Insightec Company

INSIGHTEC develops and distributes the Exablate platform, which provides noninvasive treatments for a variety of oncology and gynecology indications. The Exablate platform uses MRgFUS technology, which combines high-intensity focused ultrasound guided by magnetic resonance imaging. Focused ultrasound waves are used to safely ablate targeted tissue, ensuring a high rate of effectiveness with minimal side effects.

INSIGHTEC obtained FDA approval for its technology in 2016 and 2018. It is continuously investing in and expanding its current and investigational applications, ranging from functional neurosurgery to oncology and gynecology.
Technology: Neuromonitoring / Imaging
Industry: General Healthcare
Headquarters: Tirat Carmel, Hefa, Israel
Founded Date: 01-01-1999
Employees Number: 251-500
Funding Status: N/A
Investors Number: 11
Total Funding: $732,900,000
Estimated Revenue: $10M to $50M
Last Funding Date: 2022-09-01
Last Funding Type: Debt Financing

Visit Website
Register and Claim Ownership